Autoantibodies against apolipoprotein AI (anti-apoA-I IgGs) are prevalent in atherosclerosis-
related conditions. It remains elusive whether they improve the prognostic accuracy of the …

ApoA-1 (apolipoprotein A-1) is the main component of HDL (high-density lipoprotein) and
stabilizes PON-1 (paraoxonase-1), which prevents lipid peroxidation and oxLDL (oxidized …

Objectives Autoantibodies against apolipoprotein A1 (anti‐apoA1 IgGs) and its C‐terminal
region (cter apoA1) have emerged as an independent biomarker for cardiovascular disease …

Background Autoantibodies have been shown to play a critical role in predicting major
adverse cardiovascular events in atherosclerotic patients. We aimed to assess the …

Objective: The immune response is linked to the progression of atherosclerotic
cardiovascular disease (CVD). Free autoantibodies targeting ApoA-I (apolipoprotein AI) …

Abstract Aims Anti-Apolipoprotein A-1 auto-antibodies (anti-ApoA-1 IgG) represent an
emerging prognostic cardiovascular marker in patients with myocardial infarction or …

We aimed to determine the association between autoantibodies against apolipoprotein A-1
(anti-apoA-1 IgG) and prevalent cardiovascular (CV) disease (CVD) as well as markers of …

Objectives: Acute coronary syndrome (ACS) is the major cause of mortality worldwide and
caused mainly by atherosclerosis of coronary arteries. Apolipoprotein B100 (ApoB100) is a …

Abstract Objective Anti-Apolipoprotein A-1 autoantibodies (anti-ApoA-1 IgG) represent an
emerging prognostic cardiovascular marker in patients with myocardial infarction or …

Immune-driven inflammation plays an important part in atherogenesis and is therefore
believed to be key to the development of cardiovascular disease (CVD), which is currently …